Cardiac and vascular serious adverse events following tixagevimab-cilgavimab | Jobs Reply


On July 8, 2022, the ACTIV-3–TICO study group published a randomized controlled trial (RCT; ACTIV-3)

1

ACTIV-3–TICO study group
Tixagevimab-cilgavimab for the treatment of hospitalized patients with COVID-19: a randomized, double-blind, phase 3 trial.